Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay

AIDS Research and Human Retroviruses

Volumn 25, Issue 3, 2009, Pages 343-345

  Eshleman, Susan H ^a,d   Hudelson, Sarah E ^a   Smith, Peter ^b   Hackett Jr , John ^c   Holzmayer, Vera ^c   Swanson, Priscilla ^c   Devare, Sushil G ^c   Marlowe, Natalia ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CELERA   (United States)

^c ABBOTT DIAGNOSTICS   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ELVITEGRAVIR; INTEGRASE; POL PROTEIN; RALTEGRAVIR; VIRUS RNA; INTEGRASE INHIBITOR;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG SENSITIVITY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS MUTATION; VIRUS STRAIN; ARGENTINA; BRAZIL; CAMEROON; CLASSIFICATION; CLUSTER ANALYSIS; DNA SEQUENCE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MISSENSE MUTATION; MOLECULAR GENETICS; PHYLOGENY; SEQUENCE HOMOLOGY; SOUTH AFRICA; THAILAND; UGANDA; VIROLOGY;

ARGENTINA; BRAZIL; CAMEROON; CLUSTER ANALYSIS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PHYLOGENY; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; SOUTH AFRICA; THAILAND; UGANDA;

EID: 65449116538     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0236     Document Type: Article

References (8)

1. Pommier Y, Johnson AA, and Marchand C: Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005;4:236-248.
2. Stanford University HIV Drug Resistance Database: Integrase Inhibitor Resistance Notes. http://hivdb.stanford.edu/ cgi-bin/IIResiNote.cgi. Accessed 9/7/08.
3. Lataillade M, Chiarella J, and Kozal MJ: Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antiviral Ther 2007;12: 563-570.
4. Hackett J, Jr, Harris B, Holzmayer V, et al.: Naturally occurring polymorphisms in HIV-1 group M, N, and O integrase: Implications for integrase inhibitors. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 3-6, 2008 (Abstract 872).
5. Swanson P, Devare SG, and Hackett J Jr: Molecular characterization of 39 HIV isolates representing group M (subtypes A-G) and group O: Sequence analysis of gag p24, pol integrase, and env gp41. AIDS Res Hum Retroviruses 2003;19: 625-629.
6. Leitner T, Korber B, Daniels M, Calef C, and Foley B: HIV-1 subtype and circulating recombinant form (CRF) reference sequences. In: HIV Sequence Compendium 2005 (Leitner T, Foley B, Hahn B, et al., eds.). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 2005, pp. 41-48, LA-UR 06-0680.
7. Fransen S, Gupta S, Danovich R, et al.: Loss of raltegravir susceptibility in treated patients is conferred by multiple non-overlapping genetic pathways. Antiviral Ther 2008; 13(Suppl. 3):A9.
8. Hatano H, Lampiris H, Huang W, et al.: Virological and immunological outcomes in a cohort of patients failing integrase inhibitors. Antiviral Ther 2008;13(Suppl. 3):A12.